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ABSTRACT
Background. We aimed to describe the characteristics of immunoglobulin A nephropathy (IgAN) in Korea with assessment
for time trends.
Methods. We performed a multicenter retrospective observational cohort study including biopsy-confirmed native IgAN
cases from four tertiary hospitals in Korea. Time eras of diagnosis were stratified into 1979–2003, 2004–9 and 2010–17. The
prognostic variable was progression to end-stage kidney disease (ESKD) analyzed by multivariable Cox regression analysis.
Results. We included 1366 (from 1979 to 2003), 1636 (from 2004 to 2009) and 1442 (from 2010 to 2017) IgAN patients in this
study. In the recent periods, IgAN had relatively better clinical characteristics, as patients had higher estimated glomerular
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filtration rates and lower baseline blood pressures than before. The use of renin–angiotensin–aldosterone system (RAAS)
blockers increased from 57.7% in 1979–2003 to 80.0% in 2010–17. During a median follow-up duration of 11.3 years, 722
patients progressed to ESKD with an incidence rate of 12.5 per 1000 person-years. The 10-year risk of progression to ESKD
was lower in 2010–17 compared with that of 1979–2003 [adjusted hazard ratio 0.692 (95% confidence interval 0.523–0.915)],
even after adjustment for multiple clinicopathologic characteristics. The use of RAAS blockers was a significant mediator (P
< 0.001) for the association between time trends and lower 10-year ESKD risk.
Conclusions. Clinicopathologic characteristics of IgAN in Korea have changed over time. Although the limitation of a
retrospective observational study remains, the result showed that the prognosis of IgAN has improved over the study
period, possibly related to increased prescription of RAAS blockers.
Keywords: aldosterone receptor blockade, angiotensin-converting enzyme inhibitor, end-stage kidney disease, glomerulone-
phritis, IgA nephropathy
INTRODUCTION
Immunoglobulin A nephropathy (IgAN) is one of the most com-
mon primary glomerulonephritis globally [1, 2]. As the disease
is a major etiology of end-stage kidney disease (ESKD), many
studies have focused on the pathophysiology, characteristics
and prognosis of the disease. However, as a disease-specific bio-
marker or treatment has not been firmly established, IgAN con-
tinues to be an important disease category to be studied in the
field of nephrology.
IgAN has been widely recognized since the 1970s [3, 4] and
previous studies have since improved clinical practices and
reported useful treatment strategies for the disease, particularly
the maximum usage of renin–angiotensin–aldosterone system
(RAAS) blockers as a standard of care [5–8]. Although the under-
standing of the disease has advanced, there has been limited re-
search investigating the time trends of characteristics and
prognosis of IgAN with a sufficient number of patients [9, 10].
As the population structure is changing and clinical guidelines
have been developed [11], a study investigating whether any
distinct features are present in the different time periods re-
garding IgAN may provide insights regarding future disease
trends. In addition, as IgAN is relatively more common and
shows a worse prognosis in Asians compared with other ethnic-
ities, such evidence would be particularly important in this re-
gion [12].
In this study we aimed to evaluate the temporal trends of
characteristics and prognoses of IgAN in Korea, where a high
prevalence of IgAN is reported [13], using a large-scale, multi-
center cohort. We hypothesized that a time trend would be pre-
sent in the cohort and that the trend would be associated with
the introduction of treatment strategies for IgAN.
MATERIALS AND METHODS
Ethics approval
The institutional review boards (IRBs) of the four study hospitals
[Seoul National University Hospital (IRB No. H-1802-102-924),
Seoul National University Bundang Hospital (SNUBH; IRB No. B-
1707-408-106), Asan Medical Center (IRB No. 2017-0317) and
Severance Hospital (IRB No. 4-2017-0646)] approved the study.
The study was performed in accordance with the principles of
the Declaration of Helsinki.
Study design and study population
This study employed a multicenter retrospective cohort includ-
ing IgAN patients from the four government-designated tertiary
hospitals in Korea. We included pathology-confirmed IgAN
cases from 1979 to 2017 in the study. We excluded those who
were on maintenance kidney replacement therapy without
baseline or follow-up information. The included patients were
divided according to three time periods, which were determined
to include similar numbers of IgAN patients: 1979–2003, 2004–9
and 2010–17.
Data collection
The following clinicopathologic characteristics were collected at
the time of the initial biopsy for diagnosing IgAN: age, sex and
baseline systolic and diastolic blood pressure (BP), with calcula-
tions of mean arterial pressure (MAP; one-third of systolic BP þ
two-thirds of diastolic BP). History of diabetes mellitus or hyper-
tension was recorded. Collected laboratory parameters included
estimated glomerular filtration rate (eGFR) calculated by the
Chronic Kidney Disease Epidemiology Collaboration equation
based on serum creatinine values. The amount of baseline pro-
teinuria (PU) was measured from a 24-h urine sample; as these
data were frequently absent, the random urine protein:creatinine
ratio (uPCR) was used instead in such cases. Treatment history af-
ter the diagnosis of IgAN was reviewed. The treatment approaches
included RAAS blockers or immunosuppressants, mainly cortico-
steroids, cyclophosphamide and calcineurin inhibitors.
Pathological characteristics, including the degree of cellular or
fibrocellular crescent formation, global sclerosis, segmental sclero-
sis, tubular atrophy and interstitial fibrosis, were recorded. As the
Oxford classification had not been implemented, for global sclero-
sis and segmental sclerosis we used the cutoffs to grade the find-
ings by the criterion that was used in our previous study, which
validated the predictive role of cellular or fibrocellular crescents
[14]. The degree of cellular or fibrocellular crescents in the biopsied
tissue was stratified according to the following C scores: C0 (none),
C1 (>0–<25%) and C2 (25%) [15]. The severity of tubular atrophy
or interstitial fibrosis was graded as none (0%), mild (>0–25%),
moderate (>25–50%) and severe (>50%).
Clinical outcome assessment
The prognostic outcome was progression to ESKD defined by
the initiation of kidney replacement therapy. We reviewed the
nationwide kidney replacement therapy registry maintained by
the Korean Society of Nephrology [16]. Since the data included
information about the initiation date of the kidney replacement
therapy and modalities, we were able to identify the nationwide
outcomes. Considering that the follow-up duration was signifi-
cantly different between the time periods, the 10-year ESKD
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data that were right truncated were analyzed as the main out-
come. We also collected the ESKD outcome during the total
follow-up period. Right censoring was performed when patient
death was recorded or on 31 December 2019. The death events
were collected from Statistics Korea, which records data regard-
ing deaths for Koreans, with appropriate approval from the
organization.
Statistical analysis
Categorical variables were presented as frequencies (percentages)
and analyzed by the chi-squared test. Continuous variables were
shown as medians (interquartile ranges) and analyzed by the
Kruskal–Wallis test. We plotted Kaplan–Meier survival curves
and the log-rank method was used to calculate P-values. We also
constructed multivariable Cox proportional hazards models and
the hazard ratios (HRs) for the ESKD outcome were calculated
and adjusted for the following variables: age, sex, baseline body
mass index, eGFR (categorical, 60, 30 –<60, <30 mL/min/
1.73 m2), presence of a high BP (MAP 100 mmHg), significant PU
(random uPCR or 24-h protein 1 g/g or 1 g/day), serum uric acid
level, total cholesterol level and degree of interstitial fibrosis
(none, mild, moderate and severe) and tubular atrophy (none,
mild, moderate and severe). The details regarding other subgroup
investigations are described in the Supplemental Methods.
Whether the differences in groups of patients who received
RAAS blockers or immunosuppressants as treatment for IgAN
in different time periods mediated the differences in prognosis
was analyzed with mediation analysis. In the analysis, a uni-
variable model and the above fully adjusted multivariable
model were used and the presence of a significant mediation ef-
fect of the medication (RAAS blockers or immunosuppressants)
was tested with the ‘mediation’ package in R (version 3.6.0; R
Foundation for Statistical Computing, Vienna, Austria).
As there was missing information in the data set
(Supplemental Methods); for multivariable investigation, multi-
ple imputation was performed for the missing variables by the
chained equations method. The imputation was performed with
the ‘mice’ package in R. The imputation process was used only
for multivariable adjustments and not for reporting descriptive
statistics or dividing subgroups. The patients with missing infor-
mation for the variables used to determine subgroups were disre-
garded in the corresponding subgroup analysis.
All statistical analyses were performed with R and a two-
sided P-value <0.05 was considered statistically significant.
RESULTS
Study population
We screened 4621 biopsy-confirmed IgAN patients in the study
hospitals (Figure 1). After excluding those without baseline or
follow-up information (n¼ 117) or patients with established
ESKD (n¼ 60), a total of 4444 patients were studied. When we di-
vided the study patients according to time periods, 1366, 1636
and 1442 patients were diagnosed in 1979–2003, 2004–9 and
2010–17, respectively.
Clinicopathologic characteristics of IgAN according to
time periods
The clinicopathologic characteristics for each of the time peri-
ods are presented in Table 1. The median age at the time of di-
agnosis tended to be older; in particular, the proportion of
patients 60 years of age greatly increased in the later periods
in contrast with the earlier period. The baseline BP was lower in
the more recent periods; however, the proportion of patients
with combined hypertension increased more in the recent peri-
ods than from 1979 to 2003. The amount of PU at the time of
IgAN diagnosis tended to be lower in the recent periods. The
proportion of patients initially treated with RAAS blockers was
<60% in 1979–2003, but it notably increased with time and
reached up to 80% in 2010–17. The use of immunosuppressants
also increased with time, from 21.0% in 1979–2003 to 29.1% in
2010–17. Pathological characteristics and the degree of glomeru-
lar changes, including global sclerosis, segmental sclerosis and
crescent formation, were not different based on time periods.
Interestingly, in terms of histologic changes in the tubulointer-
stitial area, the number of patients with moderate or severe in-
terstitial fibrosis increased with time; meanwhile, the number
of patients with moderate or severe tubular atrophy decreased.
Prognosis of IgAN according to time periods
During the total follow-up of the 48 314 person-years with a me-
dian follow-up of 11.3 (interquartile range 7.5–15.4) years, 722
patients progressed to ESKD with an incidence rate of 12.5/1000
person-years. The total number of identified ESKD cases within
10 years was 560.
The number of IgAN patients who progressed to ESKD was
384 (incidence rate 14.4/1000 person-years), 239 (incidence rate
12.4/1000 person-years) and 99 (incidence rate 10.1/1000 person-
years) in the time periods of 1979–2003, 2004–9 and 2010–17, re-
spectively (Figure 2). The difference in prognosis, both in terms
of ESKD during the total follow-up and in terms of ESKD within
10 years, was significant in both univariable and multivariable
analyses, and the prognosis of IgAN patients diagnosed in 2010–
2017 showed improvement compared with that in 1979–2003,
even after multivariable adjustment (Table 2). This trend was
also identified when we separated the study patients into five
groups according to the year of diagnosis and the HRs compared
with the previous time period showed consistently decreasing
patterns (Supplementary data, Table S1). The difference in prog-
nosis was significant between IgAN patients diagnosed in 1979–
2000 and 2005–7 or afterward in the univariable analysis and be-
tween 1979–2000 and 2008–11 or afterward in the multivariable
analysis.FIGURE 1: Study population.
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Table 1. Baseline characteristics according to time periods of IgAN diagnosis
Characteristics 1979–2003 (n¼ 1366) 2004–09 (n¼ 1636) 2010–17 (n¼ 1442) P-value
Demographics
Year of biopsy, median (IQR) 1998 (1991–2001) 2007 (2005–2008) 2012 (2011–2014) <0.001
Age (years), n (%), median (IQR) 31 (21–42) 35 (24–46) 39 (27–51) <0.001
<20 281 (20.6) 289 (17.7) 208 (14.4)
20–<40 662 (48.4) 716 (43.8) 519 (36.0)
40–<60 365 (26.7) 533 (32.6) 535 (37.1)
60–<80 57 (4.2) 95 (5.8) 173 (12.0)
80 1 (0.1) 3 (0.2) 7 (0.5)
Male, n (%) 767 (56.2) 775 (47.4) 702 (48.7) <0.001
Body mass index (kg/m2), median
(IQR)
22.7 (20.6–24.9) 22.9 (20.9–25.4) 23.2 (20.8–25.6) 0.006
Comorbidities, n (%)
Diabetes mellitus 59 (5.0) 67 (4.7) 81 (6.6) 0.061
Hypertension 463 (38.4) 551 (38.3) 603 (47.6) <0.001
BP (mmHg), median (IQR)
Systolic 127 (115–140) 122.5 (113–135) 120 (111–133) <0.001
Diastolic 80 (70–90) 79 (70–85) 77 (70–85) <0.001
Mean arterial pressure 97 (87–106) 93 (84–102) 92 (83–100) <0.001
<100, n (%) 765 (58.4) 1045 (69.4) 1016 (73.9)
100, n (%) 546 (41.7) 461 (30.6) 359 (26.1)
Lab findings
Serum Cr (mg/dL), median (IQR) 1.10 (0.90–1.40) 1.00 (0.80–1.40) 0.96 (0.74–1.29) <0.001
eGFR (mL/min/1.73 m2), median
(IQR)
79.42 (55.05–104.03) 79.52 (55.70–103.41) 86.31 (57.28–112.06) <0.001
60, n (%) 966 (70.7) 1167 (71.3) 1053 (73.0)
30–<60, n (%) 285 (20.9) 350 (21.4) 282 (19.6)
<30, n (%) 115 (8.4) 119 (7.3) 107 (7.4)
uPCR (g/g), median (IQR) 1.45 (0.67–2.73) 1.00 (0.46–2.02) 1.12 (0.51–2.23) <0.001
1, n (%) 778 (64.0) 676 (50.2) 723 (54.0)
Total cholesterol (mg/dL), median
(IQR)
194 (162–230) 180 (156–210) 186 (160–215) <0.001
Triglycerides (mg/dL), median
(IQR)
138.5 (93–208) 116 (81–171) 118 (82–173) 0.001
Uric acid (mg/dL), median (IQR) 5.9 (4.7–7.1) 5.7 (4.5–7.0) 5.8 (4.7–7.1) 0.064
Treatment, n (%)
RAAS blockers 788 (57.7) 1215 (77.0) 1004 (80.0) <0.001
Immunosuppressants 287 (21.0) 422 (26.7) 365 (29.1) <0.001
Pathologic findings, n (%)
Global sclerosis 0.089
None 338 (27.4) 445 (27.8) 351 (24.6)
>0–<40 683 (55.4) 924 (57.6) 832 (58.4)
40 212 (17.2) 234 (14.6) 242 (17.0)
Segmental sclerosis 0.812
None 556 (45.1) 750 (46.8) 649 (45.6)
>0–<20 528 (42.8) 651 (40.6) 598 (42.0)
20 149 (12.1) 203 (12.7) 177 (12.4)
Crescent formation 0.090
None 973 (79.0) 1243 (77.6) 1157 (81.3)
>0–<25 238 (19.3) 321 (20.1) 235 (16.5)
25 21 (1.7) 37 (2.3) 31 (2.2)
Tubulointerstitial changes
Tubular atrophy <0.001
None 231 (19.9) 299 (19.0) 259 (19.8)
Mild 419 (36.1) 938 (59.7) 793 (60.5)
Moderate 313 (27.0) 256 (16.3) 208 (15.9)
Severe 197 (17.0) 78 (5.0) 50 (3.8)
Interstitial fibrosis <0.001
None 176 (15.1) 308 (19.6) 179 (14.0)
Mild 946 (81.1) 1130 (72.0) 857 (67.0)
Moderate 35 (3.0) 111 (7.1) 196 (15.3)
Severe 10 (0.9) 21 (1.3) 47 (3.7)
There was the following numbers of missing information in the studied data set: BP, n¼252; comorbidities for diabetes, n¼616; hypertension, n¼530; treatment his-
tory, n¼244; proteinuria, n¼543; pathologic findings, n¼183; medication history, n¼244; total cholesterol, n¼540; triglycerides, n¼2623; and uric acid, n¼877.
IQR: interquartile range.
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Subgroup analysis for prognosis of IgAN
In the subgroup analysis (Table 3), time-dependent 10-year
ESKD outcome improvement was significant only in those with
a daily PU 1 g or 1 g/g but not in those witha lower degree of
PU. When the subgroups were divided according to treatment
history recorded during the time of diagnosis, IgAN patients
treated with immunosuppressants did not show any prognosis
improvement, but those not treated by immunosuppressants
showed improved prognoses in the recent time periods.
Regarding RAAS blocker use, better prognoses were noted in the
recent periods both in those who did and did not receive initial
RAAS blocker treatment in the univariable analysis. However,
such statistical significance was not observed in those diag-
nosed in 2010–17 but not prescribed RAAS blockers, but the
patients consist of only a small number so statistical power was
not secured for the multivariable investigation.
Significance of RAAS blocker use
Among those with data regarding treatment history, treatment
with RAAS blockers was a significant mediation factor for asso-
ciations in both the univariable model (P< 0.001) and the multi-
variable model (P¼ 0.04). Treatment with immunosuppressants
showed a suspected mediation effect only on the association
between time periods and 10-year ESKD outcomes in the uni-
variable model (P¼ 0.006); however, the effect was insignificant
when the model accounted for other clinicopathologic factors
(P¼ 0.16). The improvement of IgAN prognosis was more
strongly associated with changes in other factors accompanying
the prescription of immunosuppressants than to the medica-
tion itself.
Considering the significance of RAAS blocker use, we addi-
tionally tested the association between RAAS blocker treatment
and 10-year progression to ESKD risk in subgroups categorized
based on the presence of high MAP (100 mmHg) or a high
amount of PU (1 g/g or 1 g/24 h; Table 4). The univariable and
age-/sex-adjusted model showed that RAAS blocker use was as-
sociated with lower 10-year ESKD risk only in those with both
high MAP and a high amount of PU. On the other hand, a history
of RAAS blocker use was insignificantly associated with 10-year
ESKD risk in the other subgroups with lower MAP or a lower
amount of PU.
DISCUSSION
In this study we showed the characteristics and prognoses of
IgAN in South Korea for different time periods. The number of
IgAN patients diagnosed at relatively older ages or with pre-
served kidney function has increased with time. RAAS blockers
and immunosuppressants have been more frequently pre-
scribed in recent times. The prognosis of IgAN has improved re-
cently and this improvement was associated with the
increasing use of RAAS blockers for treatment.
IgAN became widely recognized in the medical literature
from historical studies in the 1970s reporting glomerulonephri-
tis with mesangial IgA disposition [3, 4, 17]. Later studies identi-
fied that IgAN is one of the most common primary
glomerulonephritis worldwide [1, 2, 18] and the prognosis of the
disease has been reported in various regions [19, 20]. Clinical
prognostic factors, including high BP, decreased baseline kidney
function or a large amount of PU, were initially reported [21, 22],
FIGURE 2: Kaplan–Meier survival curve showing kidney survival. The x-axis indi-
cates the time from initial biopsy (years) and the y-axis indicates the cumulative
survival. The black line indicates the survival curve of the IgAN patients diag-
nosed in 1979–2003, gray line in 2004–09 and red line in 2010–17. Tables contain-
ing the number at risk are shown in the chart below the survival graph.
Table 2. Prognosis of IgAN patients according to different time periods of the diagnosis
Outcomes/groups Outcomes, n (%)
Univariable Multivariable
HR (95% CI) P-value Adjusted HR (95% CI) P-value
ESKD during total
follow-up
1979–2003 384 (28.1) Reference Reference
2004–09 239 (14.6) 0.659 (0.557–0.780) <0.001 0.874 (0.722–1.059) 0.169
2010–17 99 (6.9) 0.479 (0.380–0.604) <0.001 0.593 (0.447–0.785) <0.001
10-year ESKD
1979–2003 242 (17.7) Reference Reference
2004–09 219 (13.4) 0.744 (0.620–0.893) 0.002 1.043 (0.851–1.278) 0.687
2010–17 99 (6.9) 0.506 (0.400–0.641) <0.001 0.692 (0.523–0.915) 0.010
Multivariable model was adjusted for age, sex, baseline body mass index, eGFR (categorical, 60, 30–<60, <30 mL/min/1.73 m2), presence of a high BP (MAP
100 mmHg), significant proteinuria (random uPCR or 24-h protein 1 g/g or 1 g/day), serum uric acid level, total cholesterol level, degree of interstitial fibrosis (none,
mild, moderate and severe) and tubular atrophy (none, mild, moderate and severe). Multiple imputation was performed for missing variables using the multivariate
imputation by chained equations method.
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along with the implementation of pathologic risk scoring for the
disease, leading to the development of the Oxford classification
[15, 23]. Clinical trials have shown the benefits of RAAS blockers
in improving the prognosis of IgAN [5–8]; however, the benefits
of immunosuppressant use have not been firmly established
[24–26]. In recent times, genomic studies have investigated po-
tential disease-specific biomarkers or treatment targets [15, 27,
28]. In addition, understanding of the IgAN pathophysiology,
through formation of IgA1-containing immune complexes, has
expanded [29, 30]. With the extension of knowledge of disease
pathophysiology, novel treatment strategies have been recently
trialed for the treatment of IgAN [31–33].
Along with the above historical progress and changes in
population structure in the modern era we hypothesized that
the epidemiology of IgAN would be different in recent periods
when compared with the past. Through this study, which
includes one of the largest IgAN cohorts, we identified that the
proportion of relatively older IgAN patients has increased.
However, the proportion of patients with impaired baseline kid-
ney function or established high BP has not increased, implying
that the range of indications for biopsies might have been wid-
ened for the older population before they show overt kidney
function impairment. Additionally, changes in the general pop-
ulation structure might have led to the increasing trend of





HR (95% CI) P-value Adjusted HR (95% CI) P-value
eGFR 60 mL/min/1.73 m2
1979–2003 77/966 (8.0) Reference Reference
2004–09 42/1167 (3.6) 0.441 (0.303–0.642) <0.001 0.651 (0.458–0.925) 0.017
2010–17 21/1053 (2.0) 0.398 (0.244–0.649) <0.001 0.547 (0.320–0.936) 0.028
eGFR <60 mL/min/1.73 m2
1979–2003 165/400 (41.2) Reference Reference
2004–09 177/469 (36.2) 0.910 (0.736–1.125) 0.384 1.064 (0.842–1.343) 0.604
2010–17 78/389 (17.0) 0.601 (0.458–0.789) < 0.001 0.659 (0.475–0.914) 0.013
MAP <100 mmHg
1979–2003 93/762 (12.2) Reference Reference
2004–09 97/1039 (9.3) 0.760 (0.572–1.001) 0.058 0.789 (0.593–1.049) 0.103
2010–17 51/1009 (5.1) 0.583 (0.412–0.823) 0.002 0.549 (0.370–0.817) 0.003
MAP 100 mmHg
1979–2003 136/549 (24.8) Reference Reference
2004–09 106/467 (23.6) 0.957 (0.744–1.230) 0.729 1.011 (0.781–1.309) 0.932
2010–17 42/366 (11.5) 0.577 (0.407–0.817) 0.002 0.598 (0.405–0.883) 0.010
Proteinuria <1 g/g or g/day
1979–2003 30/436 (6.9) Reference Reference
2004–09 37/671 (5.5) 0.802 (0.495–1.298) 0.368 0.849 (0.538–1.342) 0.484
2010–17 15/615 (2.4) 0.518 (0.277–0.969) 0.040 0.551 (0.276–1.099) 0.091
Proteinuria 1 g/g or g/day
1979–2003 193/781 (24.7) Reference Reference
2004–09 148/676 (21.9) 0.920 (0.744–1.137) 0.439 0.852 (0.683–1.063) 0.156
2010–17 62/723 (8.6) 0.563 (0.431–0.734) <0.001 0.483 (0.354–0.660) <0.001
ISD positive
1979–2003 54/287 (18.8) Reference Reference
2004–09 105/422 (24.9) 1.385 (0.997–1.923) 0.052 1.106 (0.814–1.503) 0.520
2010–17 35/365 (9.6) 0.703 (0.458–1.081) 0.108 0.633 (0.397–1.009) 0.055
ISD negative
1979–2003 188/1079 (17.4) Reference Reference
2004–09 104/1157 (9.0) 0.496 (0.390–0.630) < 0.001 0.762 (0.592–0.982) 0.035
2010–17 48/890 (5.4) 0.400 (0.291–0.551) < 0.001 0.573 (0.396–0.828) 0.003
RAAS blocker
positive
1979–2003 146/788 (18.5) Reference Reference
2004–09 195/1215 (16.0) 0.866 (0.699–1.074) 0.190 0.894 (0.724–1.104) 0.299
2010–17 75/1004 (7.5) 0.540 (0.407–0.715) <0.001 0.580 (0.425–0.791) <0.001
RAAS blocker
negative
1979–2003 96/578 (16.6) Reference Reference
2004–09 14/364 (3.8) 0.218 (0.125–0.382) <0.001 0.532 (0.282–1.007) 0.052
2010–17 8/251 (3.2) 0.240 (0.116–0.495) <0.001 0.545 (0.244–1.216) 0.138
ISD: immunosuppressive drug.
Multivariable model was adjusted for age, sex, baseline eGFR (categorical, 60, 30–<60, <30 mL/min/1.73 m2), presence of a high BP (MAP 100 mmHg), significant pro-
teinuria (random uPCR or 24-h protein 1 g/g or 1 g/day), degree of interstitial fibrosis (none, mild, moderate and severe) and tubular atrophy (none, mild, moderate
and severe). Missing values were imputed using a multivariate imputation by the chained equation method.
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elderly IgAN patients as the Korean population ages [11], and
clinicians may chose more active diagnostic or therapeutic
strategies for older IgAN patients. Together with a previous re-
port, also showing the increasing prevalence of IgAN among the
elderly [10], this study suggests that IgAN in elderly patients
could be an important clinical issue in the future. Conversely,
regarding the prognosis of IgAN, the risk of progression to ESKD
has been reduced in recent periods compared with that in the
past; the progression to ESKD rate was 10.6/1000 person-years
for the cases diagnosed from 2010 to 2017. Our study provides
epidemiological evidence showing that the characteristics of
IgAN patients have been changing and the prognosis has im-
proved between time periods.
Another notable finding was that the prescription of RAAS
blockers has been widely introduced recently in Korea. Evidence
since the 1990s demonstrating the benefits of RAAS blockers in
terms of IgAN prognosis is likely attributable to this phenome-
non [6, 7]. Moreover, the improvement in prognosis of IgAN
patients was significantly associated with the increased pre-
scription of RAAS blockers. As identified in our results, those
with both high MAP (100 mmHg) and a high-degree PU (1 g/g
or 1 g/24 h) may be actively prescribed RAAS blockers as sug-
gested in the current clinical guideline [34].
However, increased use of immunosuppressants was not a
significant mediator for the association between time periods
and prognosis in the multivariable model. In addition, among
those who received immunosuppressive medications, improve-
ment of prognosis according to time periods was not observed.
This may imply that the prognosis of those who required im-
mune suppression, possibly the high-risk group with rapid clini-
cal deterioration, has not been improved. In addition, the
benefits of immunosuppressive medication have yet to be
firmly established, which may partially explain the lack of prog-
nostic improvement in this patient group [24, 25]. This suggests
the necessity of a future study investigating treatment strate-
gies for IgAN patients with rapidly progressing kidney dysfunc-
tion or who are at high risk of ESKD.
Our study has several limitations. First, the recent time era
had a relatively short follow-up duration. We made efforts to
compensate for this by establishing ESKD within 10 years as an
outcome; however, the difference could not be completely com-
pensated for. Nonetheless, when we divided the study popula-
tion into five groups, patients diagnosed from 2005 to 2007 who
completed the 10-year follow-up showed a better prognosis
than those diagnosed in 2000 or earlier. A future study with a
longer follow-up period may enable us to robustly compare the
prognosis between time periods and evaluate whether the prog-
nostic risk factors have been altered. Second, as the study eval-
uated outcomes over a long period of time, heterogeneity in
terms of certain factors, including socioeconomic characteris-
tics or clinical behaviors, might have been present. In addition,
up-to-date pathologic information (e.g. Oxford classification or
vascular lesions [35]) was not available in the past pathologic
records. Third, although the study included a large number of
IgAN patients comparable to that of other large cohorts globally,
there were still IgAN patients in other major hospitals in the na-
tion who were not included. In addition, the study included a
limited number of patients of ethnicities other than Asian.
Therefore the possibility of selection bias should be considered
when interpreting the results of our study and additional exter-
nal validation may be necessary to confirm the findings. Lastly,
due to its retrospective, observational nature, there could be
hidden confounders that were not included in the current
study. In addition, the prescribed medications for RAAS block-
ade were uncontrolled and heterogeneous among the study
patients, so information of RAAS blocker dosage, compliance or
withdrawal could not be included in this study.
In conclusion, temporal trends in the characteristics of
biopsy-confirmed IgAN in the Korean cohort were noted and
the proportion of elderly IgAN patients is increasing. The overall
prognosis of IgAN showed a trend of improvement, particularly
in those without reduced eGFR but with significant PU, and this
was associated with the increasing proportion of patients
treated with RAAS blockers. Clinicians may utilize the results of
this study for understanding the recent trends of IgAN and pre-
paring future strategies for the disease.
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Table 4. Association between RAAS blockade usage and risks of progression to ESKD within 10 years in various subgroups




HR (95% CI) P-value Adjusted HR (95% CI) P-value
MAP <100 mg and PU <1 g/g or 1 g/24 h
No RAAS blocker use 10/404 (2.5) Reference Reference
RAAS blocker use 33/756 (4.4) 1.881 (0.927–3.819) 0.080 1.645 (0.781–3.464) 0.191
MAP 100 mg and PU <1 g/g or 1 g/24 h
No RAAS blocker use 7/99 (7.1) Reference Reference
RAAS blocker use 25/313 (8.0) 1.143 (0.494–2.643) 0.755 0.997 (0.422–2.358) 0.995
MAP <100 mg and PU 1 g/g or 1 g/24 h
No RAAS blocker use 29/251 (11.6) Reference Reference
RAAS blocker use 136/951 (14.3) 1.280 (0.857–1.911) 0.228 1.038 (0.682–1.581) 0.861
MAP 100 mg and PU 1 g/g or 1 g/24 h
No RAAS blocker use 59/145 (40.7) Reference Reference
RAAS blocker use 172/477 (26.5) 0.610 (0.454–0.820) 0.001 0.680 (0.500–0.924) 0.014
The multivariable model was adjusted for age and sex.
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